Awards Golden Ticket to Auxocell Laboratories, Inc., an innovator in stem cell therapeutics and regenerative medicine
CAMBRIDGE, Mass. – November 16, 2016 − Executive search firm Slone Partners is proud to contribute to the growth and development of the biotech and life sciences industries by sponsoring LabCentral, a first-of-its-kind shared laboratory space, which serves as a launchpad for high-potential startups.
Founded in November 2013, LabCentral is a private, nonprofit organization providing a full range of services and programs to support the laboratory and business operations of early-stage companies. Located in the heart of the Cambridge biotech innovation hub, LabCentral offers laboratory and office space to as many as 30 biotech and life sciences startups. The facility houses approximately 125 entrepreneurs and scientists at a time, and to date, has seen 21 resident companies graduate to alumni status.
“Through its sponsorship of LabCentral, Slone Partners contributes to the advancement of the industry by providing strategic business guidance to organizations. Whether they are in startup mode or well-established, we are involved in every step of the hiring process to ensure these organizations are equipped with robust hiring strategies to compete in the market,” stated Leslie Loveless, CEO of Slone Partners.
As a Gold sponsor, Slone Partners can help sponsor an early-stage company’s residency at LabCentral’s Kendall Square facility through LabCentral’s Golden Ticket program. Slone Partners has elected to award its 2016 Golden Ticket to Auxocell Laboratories, Inc., which manufactures solid-tissue-processing equipment critical to innovation in cellular therapies. Each Golden Ticket represents a priority spot for residency ahead of other companies and/or a voucher for prepaid rent for one reserved bench in LabCentral’s shared laboratory for one year.
“LabCentral’s mission is to help create the next generation of powerhouse companies by providing entrepreneurs with the space and resources they need to nurture early ideas,” said LabCentral Co-Founder and President Johannes Fruehauf, M.D., Ph.D. “Slone Partners’ involvement goes beyond their sponsorship. Their participation encourages all our resident companies to use their expert counsel and guidance to increase their odds of success.”
About Slone Partners
Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life sciences, clinical trials, contract research, healthcare information technology and laboratory testing industries with offices in Boston, Washington, D.C. and San Francisco.
About LabCentral (www.labcentral.org; twitter @labcentral)
A 28,000 square-foot facility in the heart of the Kendall Square, Cambridge, biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for early-stage companies comprising approximately 125 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that startups need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by a $5 million grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation.
About Auxocell Laboratories, Inc.
Auxocell continues to be an innovator in the regenerative-medicine field with the release of its Auxocell Processing (AC:Px) System, a patented tool for processing solid tissue. The Auxocell research team relied upon their decades of experience in solid tissue processing to design and manufacture the AC:Px. The AC:Px system is available exclusively from Auxocell.
Related content: Slone Partners Co-Sponsors the Precision Medicine Leaders Summit
Press release edited on 6/28/2023